Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.53 |
| ▸ | CA1 | P00915 | 5/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.53 |
| ▸ | CA9 | Q16790 | 5/20 | 0.53 |
| ▸ | SUCNR1 | Q9BXA5 | 7/20 | 0.47 |
| ▸ | RARB | P10826 | 3/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30504190 | 1.00 | CA12 (0.53) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL22280880 | 1.00 | CA12 (0.53) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL22280681 | 1.00 | CA12 (0.53) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL22280542 | 0.99 | CA12 (0.52) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL30504195 | 0.99 | CA12 (0.52) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL22280842 | 0.97 | CA12 (0.50) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL30504183 | 0.97 | CA12 (0.50) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL30504168 | 0.95 | CA12 (0.48) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL22280539 | 0.95 | CA12 (0.48) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL22280684 | 0.95 | CA12 (0.55) | CA12CA1CA2CA9SUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891558-B2 | Solid foam comprising mesogenic ligand-functionalized nanoparticles and methods of making and using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-06 | — | — | US | disclosed |
| US-11708530-B2 | Organic ligands for templatable mesoscale nanocapsules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708530-B2 | Organic ligands for templatable mesoscale nanocapsules | EPCAM, L1CAM, ICOSLG | CA12 1269/4885CA1 1575/4885CA2 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.